This sponsored supplement was produced by Focus Reports.
Project Director: Koen Liekens
Project Coordinator: Maria Elena Gomez
Project Publishers: Julie Avena
Contributors: Joan Abellan, Xenia Radu
For exclusive interviews and more info, please log onto
or write to firstname.lastname@example.org
Ask Indonesians about a bad experience in medical care and each will have a story to tell. The poor state of Indonesia's health
care system has turned 'improving quality' into the top priority of the government of Indonesia. Better quality of care has
become especially important as the fourth most populated country in the world moves into full traction with its plans to achieve
universal health care coverage.
(SOURCE: ARTISANS OF BALI, HTTP://ARTISANSOFBALI.COM)
According to the Ministry of Health, 72 percent of the population, just over 176 million Indonesians, were already part of
some type of health financing scheme. Now Indonesia's policymakers are committed to covering every citizen by 2019. The implementation
of universal health care coverage will start in January 2014 and is widely seen as a significant step forward for Indonesia's
238 million people.
Badan Penyelenggara Jaminan Sosial, BPJS as the system is locally referred to, aims to drastically increase the quality and
access to medicines and medical treatment to the entire Indonesian population. From policymakers to health care providers,
drug manufacturers to distributors, all stakeholders in Indonesia's health care and pharmaceutical sector are now facing the
critical task of defining their role within this changing environment.
Most multinational companies (MNCs) do not expect to play a major role within BPJS but, despite the vast volume, serving BPJS
will not be easy or cheap for local manufacturers either. Not only are they required to ramp up manufacturing capacity to
serve a growing market, permits to manufacture –due to Indonesia's Pharmaceutical Inspection Convention and Pharmaceutical
Inspection Co-operation Scheme (jointly referred to as PIC/S) adherence– have become stricter than ever.
Key Indicators Indonesia
Increasingly important within Indonesia's changing pharmaceutical landscape is the role of the distributor. Not only will
distributors play a key role in making universal healthcare coverage a reality by physically making medical devices and medicines
available across Indonesia's complex geography, they will also play an essential role in identifying where and how the market
will benefit from BPJS by providing the manufacturer with the latest data from the field.
Courtesy of Sanofi
Promising macro-economic data, exponential growth rates, demographic potential, and a growing middle class have drawn Indonesia
into the international spotlight, earning a place among the world's 'pharmerging' countries. Executives should not stare themselves
blind on the double digit growth rate however. Indonesia remains a market where both MNCs and local pharmaceutical companies
can enjoy steep growth curves-- provided they are willing to invest in the long run. These long term investments can take
on various formats, including manufacturing, partnering, and brand building. All will be central to function as an agent of
change while Indonesia heads towards universal health care coverage.
Dr. Nafsiah Mboi, Minister of Health